SLC5A2 and diabetes mellitus: This is particularly important for SGLT2 inhibitors because diabetes therapies have historically seen large manufacturer discounts, suggesting that actual prices faced by payers may be highly variable and subject to negotiation with manufacturers.7 We therefore evaluated the cost-effectiveness of adding dapagliflozin to GDMT for the management of HFrEF in patients with or without diabetes at baseline from a US health care sector perspective and a lifetime analytic horizon.